Elevance Health Earnings Lift 2026 Guidance
Elevance Health earnings Q3 2026 raised full-year guidance and the 2026 baseline, likely prompting traders to reprice EPS and cash-flow expectations.
KEY TAKEAWAYS
- Raised full-year 2026 adjusted diluted EPS guidance to at least $29.00 and diluted EPS to at least $22.00.
- Raised 2026 earnings baseline to at least $26.75 and set a 2027 adjusted EPS growth target of 12%.
- Q3 adjusted diluted EPS was $6.99, including a $1.85 net non-operating benefit; operating cash flow was $1.3 billion.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Elevance Health reported stronger third-quarter results on Oct. 21, 2026, prompting the company to raise full-year 2026 adjusted EPS guidance and lift its earnings baseline. These moves reshape Elevance Health earnings expectations and tighten the 2027 growth framework.
Third-Quarter Results and Updated Guidance
Elevance Health Inc. (ELV) posted operating revenue of $50.4 billion for the quarter ended Sept. 30, 2026, a 0.7% increase from the prior year. Diluted EPS was $6.27, while adjusted diluted EPS reached $6.99, boosted by a net non-operating benefit of $1.85 per share. Operating cash flow totaled $1.3 billion. The company raised its full-year 2026 guidance to at least $22.00 diluted EPS, $29.00 adjusted EPS, and $6.5 billion in operating cash flow. The official release stated, “Elevance Health’s third quarter results reflect stronger execution across our diversified portfolio and underscore the earnings power of the business.”
Business Drivers and Earnings Baseline
Management attributed the quarter’s outperformance to improved results across Medicaid, Medicare Advantage, and the Individual ACA business, along with higher premium yields, CarelonRx product and service revenue, and favorable medical-cost performance. Approximately $0.50 per share of the adjusted EPS beat came from operating performance. Secondary summaries noted that Carelon’s cancer program reduced avoidable inpatient admissions by 15%, though the official release did not independently confirm this figure.
The company raised its 2026 earnings baseline to at least $26.75 per share, an increase of $0.75, establishing this as the starting point for a 2027 framework targeting at least 12% adjusted EPS growth. The revised adjusted EPS outlook reflects operating momentum combined with favorable non-operating items, including a non-recurring discrete tax item expected in the fourth quarter of 2026. Management described the higher baseline as reflecting underlying operating results and an improved outlook for the Individual ACA segment.
No new regulatory approvals, enforcement actions, or government decisions were disclosed in the earnings release or call materials.
